Trial Profile
Potential Therapy With MACITENTAN in the Treatment of Chronic Lung Allograft Dysfunction (CLAD) After Lung Transplantation
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase IV
Latest Information Update: 05 Nov 2021
Price :
$35
*
At a glance
- Drugs Macitentan (Primary)
- Indications Lung transplant rejection
- Focus Therapeutic Use
- 09 Dec 2020 Planned primary completion date changed from 1 Feb 2020 to 19 Sep 2019.
- 09 Dec 2020 Status changed from not yet recruiting to withdrawn prior to enrolment.
- 27 Sep 2016 New trial record